Bio Break: Finding the Path to MedTech Innovation with the Pathfinder Program
Pathfinder Program MedTech Innovation
In this Pathfinder Program MedTech Innovation episode of Bio Break, Nick Allan and Joris explore one of the most dynamic early-phase services at StarFish Medical: the Pathfinder Program. If you’re a medtech innovator with a promising concept or prototype, Pathfinder helps you identify the right path forward—before you invest millions in development.
Nick explains that Pathfinder projects focus on structured, interdisciplinary exploration to de-risk early innovation decisions. Whether it’s a new diagnostic platform or a novel therapeutic device, these short, intensive engagements are designed to define your target product profile, investigate regulatory and IP strategy, and uncover unmet user needs—all before a single part is manufactured.
The episode discusses how the Pathfinder team collaborates across human factors, industrial design, systems engineering, and sometimes even early prototyping to assess feasibility and market alignment. The outcome? A comprehensive Pathfinder Report. This document helps clients understand competitive positioning, reimbursement potential, freedom to operate, and how to prioritize the product’s unique value in the clinical space.
Joris and Nick also reflect on how Pathfinder enables clients to avoid costly pivots later in the process. By bringing in industrial designers and regulatory experts early, teams can explore device form factor, usability constraints, and even conduct basic visualizations or 3D-printed proofs-of-concept.
Whether you’re preparing for a funding round, seeking to understand your market fit, or building a go-to-market strategy, the Pathfinder Program can give your team clarity and confidence. Tune in to see how this process sets the foundation for successful medical device commercialization—and why it’s one of the most rewarding project types at StarFish.
Learn more about StarFish Medical.
Related Resources
Connected health devices are multiplying fast. We examine the gap between remote monitoring’s promise and its reality.
Ariana and Mark walk through what separates a clinical prototype from a proof-of-concept build, what determines how much testing and documentation you actually need, and where the regulatory line between significant risk and non-significant risk falls.
In this episode of Bio Break, Nick walks through both patent types after receiving two of his own in the mail, one of each, from the USPTO.
Scott Phillips sits down with Mickey Urdea to examine what actually distinguishes companies that reach commercial outcomes from those that do not.